HUTCHMED (NASDAQ:HCM) Shares Gap Down – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM) shares gapped down prior to trading on Tuesday . The stock had previously closed at $14.89, but opened at $14.50. HUTCHMED shares last traded at $14.35, with a volume of 8,301 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research note on Friday, March 21st.

HUTCHMED Stock Down 3.5 %

The firm has a 50-day moving average price of $14.77 and a 200-day moving average price of $16.12. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in HUTCHMED in the 3rd quarter worth about $35,000. Barclays PLC grew its stake in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after acquiring an additional 2,255 shares during the period. Blue Trust Inc. raised its holdings in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after purchasing an additional 3,532 shares during the last quarter. Summit Trail Advisors LLC lifted its position in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after purchasing an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC purchased a new stake in HUTCHMED in the fourth quarter worth approximately $230,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.